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Main Text 
Chronic myeloid leukemia (CML) is a paradigmatic tumor in oncology research. It was the 
first cancer in which a recurrent chromosomal abnormality, the Philadelphia chromosome 
arising from the reciprocal translocation between chromosomes 9 and 22, was identified and 
subsequently shown to be pathogenic through the production of the fusion oncogene and 
tyrosine kinase (TK) BCR-ABL. CML also perfectly fits the cancer stem cell model as it arises 
from a leukemic stem cell (LSC) which represents the reservoir of the disease and, through 
self-renewal and differentiation, is able to generate the tumor bulk of mature leukemic cells. 
Finally, the development of BCR-ABL tyrosine kinase inhibitors (TKI) represented the first 
example of a scientifically validated and highly specific targeted therapy in oncology. Although 
BCR-ABL TKI have greatly improved patient outcome, with the majority of chronic phase 
(CP) CML patients achieving deep molecular responses and having life expectancies similar 
to age-matched population, they are not curative. BCR-ABL+ LSC and BCR-ABL genomic 
DNA can be detected in patients with undetectable BCR-ABL transcript levels in peripheral 
blood and several clinical studies show that around 50% of the small proportion of patients 
achieving sustained deep molecular responses will molecularly relapse upon TKI 
discontinuation. Preclinical studies have shown that CML LSC are resistant to TKI, despite 
effective BCR-ABL TK inhibition, thus explaining TKI inability to cure CML. This latter 
observation suggests CML LSC rely on other survival pathways and several putative 
candidates have been reported as potential therapeutic targets to eradicate LSC and achieve 
disease cure(1).  
Amongst these, the intracellular tyrosine kinase janus kinase (JAK) 2 has been shown to 
support CML LSC survival, particularly via signal transducer and activator of transcription 
(STAT) 3 and 5 activation in response to hematopoietic growth factors stimulation, and several 
preclinical studies have shown that JAK2 inhibitors are able to eliminate CML LSC. This latter 
observation coupled with the availability of numerous clinical grade JAK2 inhibitors, currently 
licensed for the treatment of BCR-ABL- myeloproliferative neoplasms, has now allowed for 
the translation of these preclinical findings into a clinical trial in CML patients(2).  
In this issue of Leukaemia Research, Sweet and colleagues report the tolerability, safety and 
preliminary efficacy results of a Phase I clinical trial investigating the combination of the JAK2 
inhibitor ruxolitinib with the second generation BCR-ABL TKI nilotinib for 6 months in 11 
CP CML patients with evidence of residual disease at molecular level(3). Although the findings 
of this study need to be interpreted with caution given the small number of patients and the 
lack of randomized comparison with single agent TKI, the authors report several interesting 
observations. First, ruxolitinib in combination with nilotinib appears to be well tolerated with 
no dose-limiting toxicity identified although grade 1/2 anemia was observed in almost 40% of 
patients, all of which in the cohort treated with highest ruxolitinib dose (i.e. 15mg BD). Second, 
molecular responses in this small cohort was encouraging with median change in BCR-ABL 
transcripts of 1 log after 6 months of combination treatment. One patient had progressive 
disease but analysis of the diagnostic material suggested that progression had likely started 
prior to study entry. Intriguingly, the authors show that the proportion of patients achieving 4.5 
log reduction in BCR-ABL transcript levels relative to baseline levels, i.e. Molecular Response 
(MR) 4.5, over 6 months was 40% which is higher than reported in the nilotinib arm of the 
phase 3 ENESTnd trial, where cumulative rates of MR4.5 over any 6 months period on nilotinib 
were 5-10%(4). Finally, the authors show that plasma from patients treated with ruxolitinib 
was able to inhibit STAT3 and 5 phosphorylation in cell lines compared to pretreatment plasma 
from the same patients, thus providing correlative evidence of the on-target effects of this JAK2 
inhibitor.  
Several questions however remain to be answered in regards to the efficacy and safety of JAK2 
inhibitors in CML patients. Although tolerability of the combination treatment in CP CML 
patients appears reassuring based on the authors’ data, ruxolitinib can cause anemia and more 
widely cytopenias, as also observed in the study. Given that most CP CML patients on TKI 
enjoy a near normal quality of life, larger studies will clarify if this therapeutic approach results 
in increased hematological toxicity which might influence clinicians and patients’ decision to 
use JAK2 inhibitors in this population and limit its use to patients who show no hematological 
toxicity in response to TKI.  Also, as CML LSC resistance mechanisms to TKI are multiple, it 
will be useful to characterize genetic and transcriptional features of CML LSC from patients at 
study entry and correlate these features with their outcome to identify predictors of response to 
this combined approach. These correlative studies might also help to understand if other 
described mechanism through which JAK2 supports CML LSC survival, such as direct 
activation of MYC and β-catenin(2), play a role in vivo in patients. Finally, it would be tempting 
to test if such an approach might prove useful in advanced phase/resistant CML. However, 
given that in advanced phase/resistant disease BCR-ABL TK is often not fully inhibited 
because of BCR-ABL TK domain mutations, caution should be exercised based on evidence 
that deletion of JAK2 might accelerate CML development in mouse models by preferentially 
causing elimination of normal hematopoietic stem cell compared to CML LSC where BCR-
ABL is still active(5). 
In conclusion, the work from Sweet and colleagues provides a framework for CML LSC 
directed clinical trials which could be extended also to other targets identified and validated in 
preclinical studies, such as EZH2, P53 and MYC(1). More specifically, it represents a 
springboard for further phase 2 studies testing the role of JAK2 inhibitor in CML, with some 
already ongoing in other centers (NCT01751425), and ideally comparing in a randomized 
approach JAK2 plus BCR-ABL inhibitor combination treatment versus single agent TKI as the 
authors are planning. These future studies will hopefully confirm the authors’ findings, 
characterize better the mechanisms and predictors of response to JAK2 inhibitors in CML 
patients and provide a cure for a proportion of the fast-growing CML patient population. 
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